ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Moderate Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $107.3333.

Several research firms recently issued reports on ANIP. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th.

ANI Pharmaceuticals Stock Down 0.2%

ANIP opened at $74.67 on Friday. The firm has a market capitalization of $1.68 billion, a P/E ratio of 22.22 and a beta of 0.52. ANI Pharmaceuticals has a one year low of $56.71 and a one year high of $99.50. The company has a fifty day moving average price of $78.66 and a 200-day moving average price of $84.64. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 5,323 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total value of $415,300.46. Following the completion of the transaction, the insider owned 84,840 shares of the company’s stock, valued at $6,619,216.80. The trade was a 5.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 7,312 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the transaction, the chief financial officer directly owned 185,543 shares in the company, valued at $14,008,496.50. The trade was a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 27,860 shares of company stock worth $2,114,771. 11.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. Finally, State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.